Valneva (NASDAQ:VALN) Shares Up 2.3% – Here’s Why

Valneva SE (NASDAQ:VALN) shot up 2.3% during trading on Friday . The stock traded as high as $7.45 and last traded at $7.42. 6,542 shares were traded during mid-day trading, a decline of 75% from the average session volume of 25,882 shares. The stock had previously closed at $7.25.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Valneva in a report on Friday.

Valneva Stock Performance

The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The firm’s 50 day simple moving average is $6.34 and its 200-day simple moving average is $5.59. The company has a market cap of $582.64 million, a price-to-earnings ratio of -55.15 and a beta of 1.93.

Valneva (NASDAQ:VALN) last announced its earnings results on Wednesday, March 19th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The business had revenue of $56.48 million for the quarter, compared to analyst estimates of $55.64 million. On average, sell-side analysts predict that Valneva SE will post 0.13 EPS for the current year.

Institutional Investors Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA purchased a new stake in shares of Valneva SE (NASDAQ:VALN) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 19,244 shares of the company’s stock, valued at approximately $84,000. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.